Last reviewed · How we verify
NCT05820165
Brain Imaging in Cerebral Venous Outflow Disturbance
trial testing high-resolution 3D-T1 in Abnormal Cerebral Venous Sinus Morphology in 80 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Capital Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 1 March 2023 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- high-resolution 3D-T1
- diffusion tensor imaging (DTI)
- resting-state functional magnetic resonance imaging (rs-fMRI)
- arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI)
- susceptibility-weighted images (SWIs)
Conditions studied
- Abnormal Cerebral Venous Sinus Morphology — all drugs for Abnormal Cerebral Venous Sinus Morphology →
- Internal Jugular Vein Stenosis — all drugs for Internal Jugular Vein Stenosis →
- Image — all drugs for Image →
Sponsor
Capital Medical University
Who can join
18 and older, any sex, with Abnormal Cerebral Venous Sinus Morphology or Internal Jugular Vein Stenosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cerebral venous outflow disturbance can lead to cerebral hemodynamic disturbances, altered cerebrospinal fluid dynamics, cerebral venous blood stasis, increased cerebral venous pressure and decreased cerebral perfusion, cerebral white matter sparing-like changes, and widening of retinal vessel diameter. These changes are associated with numerous neurological signs and symptoms. Therefore, understanding the brain structural and functional changes in patients with cerebral venous outflow disturbance is essential to provide specific imaging evaluation indicators and new diagnosis and treatment methods for patients with cerebral venous return disorders.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05820165
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Capital Medical University trials
Trials by the same sponsor.
- NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
- NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07513233 — Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) · Phase 1 · not yet recruiting
- NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05820165 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
- Last refreshed: 19 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05820165.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing